Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06554795 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
A Phase 1 study of Solid Tumor, Adult, sponsored by DualityBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT06554795: Recruiting Phase 1 study of Solid Tumor, Adult, sponsored by DualityBio.
NCT06554795 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by DualityBio. The registered enrollment target is 360 participants, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (94% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06554795, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by DualityBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
Primary Outcome
Percentage of participants with TEAEs graded according to NCI CTCAE v5.0
Conditions Studied
Interventions
- DRUG DB-1419
Study Locations (20)
California
- Site USA12-0 - Los Angeles
- Site USA08-0 - Newport Beach
- Site USA13-0 - Sacramento
New South Wales
- AUS03-0 - North Ryde
- AUS01-0 - Randwick
Anhui
- Site CHN24-0 - Hefei
- Site CHN39-0 - Hefei
District of Columbia
- Site USA06-0 - Washington D.C.
Florida
- Site USA02-0 - Florida City
Illinois
- Site USA11-0 - Chicago
North Carolina
- Site USA03 - Huntersville
Pennsylvania
- Site USA05-0 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What NCT06554795 shows while recruiting
NCT06554795 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (94% higher).
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which DB-1419 is the first listed.
NCT06554795 names 20 study sites across 16 states, led by California, New South Wales, Anhui.
Frequently Asked Questions
What is clinical trial NCT06554795 about?
NCT06554795 is a clinical study titled "First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors". A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
What is the current status of trial NCT06554795?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 360 participants. The study started on 2024-09-03. Estimated completion is 2027-02.
What conditions does trial NCT06554795 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT06554795?
The interventions under investigation include: DB-1419 (DRUG).
Who is sponsoring clinical trial NCT06554795?
This trial is sponsored by DualityBio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06554795 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06554795's enrollment target sits among peer trials
360 11th of 72 higher than 62 of 72 other Solid Tumor, Adult trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI